

Connecting via Winsock to STN
LOGIND:SSPTPARH1626

LEGAL REPRESENTATIVE: Kirton & McConkie, Krieger, Michael F.
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Welcome to STN International! Enter x:x

PASSWORD: *

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'USPATFULL', USPAT2, AT 13:08:14 ON 04 APR 2007

FILE 'USPATFULL', ENTERED AT 13:08:14 ON 04 APR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2', ENTERED AT 13:08:14 ON 04 APR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2', ENTERED AT 13:08:22 ON 04 APR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2', ENTERED AT 13:08:22 ON 04 APR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2', ENTERED AT 13:08:22 ON 04 APR 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

FULL ESTIMATED COST

CCST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY

TOTAL SESSION

=> s 114 and migraine/ab

L15 0 L14 AND MIGRAINE/AB

=> s 114 and migraine

L16 3 L14 AND MIGRAINE

=> s 114 and migraine/ab

L17 60 L14 AND MIGRAINE/AB

=> d ibib abs 60

L17 ANSWER 60 OF 60 USPAT2 on STN Full-text

ACCESSION NUMBER: 2002-27500 USPAT2 Full-text

TITLE: Method of treating migraines and pharmaceutical compositions

INVENTOR(S): Simitchieva, Kremena, Basking Ridge, NJ, United States

McKinney, Scott A., New Hope, PA, United States

Sandquist, Eric J., Doylestown, PA, United States

Khanna, Deepak K., Tullytown, PA, United States

Hargreaves, Richard, Tullytown Park, United Kingdom

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

NUMBER ----- DATE -----

PATENT INFORMATION: US 6384034 B2 20030507

DOCUMENT TYPE: US 2001-034823 (9)

FILE SEGMENT: Continuation of Ser. No. US 1999-429274, filed on 29 Oct 1999, now abandoned

PRIMARY EXAMINER: Jarvis, William R. A.

ASSISTANT EXAMINER: Kim, Vickie

SECONDARY EXAMINER: Yuro, Raynard, Billups, Richard C., Rose, David L.

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1

LINE COUNT: 345

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination of a SHT-sub 1B/ID agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.

=> d ibib abs 59

L17 ANSWER 59 OF 60 USPAT2 on STN Full-text

ACCESSION NUMBER: 2006-175340 USPAT2 Full-text

TITLE: Benzodiazepine CGRP receptor antagonists

INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, United States

Stump, Craig A., Pottstown, PA, United States

Williams, Theresa M., Harleysville, NJ, United States

NUMBER ----- DATE -----

PATENT INFORMATION: US 2000-185913P 20000229 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Dodson, Shelley A.

ASSISTANT EXAMINER: George, Konata M.

The compound (I) may be prepared, for example, by cyclizing a compound of formula (II).
##STR2##

PATENT INFORMATION:
PATENT NUMBER: US 7196079 B2 20070327
APPLICATION INFO.: WO 2005000807 20050106 (10)
DOCUMENT TYPE: US 2004-562288 20040624
FILE SEGMENT: WO 2004-US20206 20040624

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PRIORITY INFORMATION:
PATENT NUMBER: US 2003-482674P DATE 20030626 (60)
DOCUMENT TYPE: UTILITY GRANTED

PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Rose, David L., Rubin, David
NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1
LINE COUNT: 1945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I:

##STR1## (where variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 58

L17 ANSWER 58 OF 60 USPATFULL ON STN
ACCESSION NUMBER: 91:62007 USPATFULL Full-text
TITLE: Indole derivative

INVENTOR(S): Oxford, Alexander W., Royston, England (non-U.S. corporation)
PATENT ASSIGNEE (S) :

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT INFORMATION:
APPLICATION INFO.: US 1989-317682 19890301 (7)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1987-82266, filed on 7 Aug
1987, now abandoned which is a continuation of Ser. No.
US 1985-761392, filed on 1 Aug 1985, now abandoned

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT NUMBER: GB 1984-19575 DATE 19840801
DOCUMENT TYPE: Utility Granted

PRIMARY EXAMINER: Ceperley, Mary E.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1.5

LINE COUNT: 1276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of formula (I) ##STR1## and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine.

The compound (I) may be prepared, for example, by cyclizing a compound of formula (II).
##STR2##
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to, among other things, methods of treatment of migraine headache in humans with reduced side effects by the topical administration of a migraine -ameliorating effective amount of an opioid, singly, or in combination with other

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L17 ANSWER 57 OF 60 USPATFULL ON STN
ACCESSION NUMBER: 1998-45217 USPATFULL Full-text
TITLE: Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine

INVENTOR (S) : Cohen, Marlene L., Carmel, IN, United States
Johnson, Kirk W., Indianapolis, IN, United States
Phebus, Lee A., Fountaintown, IN, United States
Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

PATENT ASSIGNEE (S) : NUMBER KIND DATE
US 5744482 Utility 1994-318391
US 19941005 (8)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT INFORMATION:
APPLICATION INFO.: US 5455907 1999-12-14 USPATFULL Full-text
DOCUMENT TYPE: Utility 19991015 19990105 (8)
FILE SEGMENT: Method of treatment of migraine
PRIMARY EXAMINER: Peyman, Ghobam A., 202 Gravier, Suite B, New Orleans,
LA, United States 70112-2234
INVENTOR (S) : NUMBER KIND DATE
US 5455907 Utility 19970324 19970324 (8)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to, among other things, methods of treatment of migraine headache in humans with reduced side effects by the topical administration of a migraine -ameliorating effective amount of an opioid, singly, or in combination with other

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to, among other things, methods of treatment of migraine headache in humans with reduced side effects by the topical administration of a migraine -ameliorating effective amount of an opioid, singly, or in combination with other

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to, among other things, methods of treatment of migraine headache in humans with reduced side effects by the topical administration of a migraine -ameliorating effective amount of an opioid, singly, or in combination with other

pharmacological agents, including vasoconstrictors, antiinflammatory agents, antimicrobial agents, decongestants and non-opioid migraine drugs.

Annedi, Subhash C., Mississauga, CANADA

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 117 and crystalline
L18 11 L17 AND CRYSTALLINE

=> d ibib abs tot

L18 ANSWER 1 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2007:64617 USPATFULL Full-text
TITLE: Preemptive prophylaxis of migraine
INVENTOR(S): Cady, Roger K., 631 Riverview Rd., Ozark, MO, UNITED STATES 65721
Guterman, Donna Lee, c/o Glaxo Wellcome Inc. Five Moore Dr., P.O. Box 13398, Research Triangle Park, NC,
UNITED STATES 27709-3398
O'Quinn, Stephen Venson, c/o Glaxo Wellcome Inc. Five Moore Dr., P.O. Box 13398, Research Triangle Park, NC,
UNITED STATES 27709-3398

PATENT INFORMATION:
APPLICATION INFO.: US 2000-575277 20000522 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1999-US9414, filed on 29 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-185310, filed on 3 Nov 1998, Pat. No. US 6066092

PATENT INFORMATION:
APPLICATION INFO.: US 1997-64879P 19971106 (60)
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kim, Vickie
LEGAL REPRESENTATIVE: Husch & Eppenberger LLC, Rusche, H. Frederick
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of preventing the headache phase of migraine in a human comprises administration of a 5HT₁ receptor agonist or administration of an over-the-counter or nonprescription drug to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the 5HT₁ sub.1 agonist or over-the-counter or nonprescription drug. There is disclosed a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task, and interpreting the results as a percent of baseline indicator of need for prophylaxis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:2713924 USPATFULL Full-text

TITLE: CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DOCUMENT TYPE: Utility APPLICATION
FILE SEGMENT: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
LEGAL REPRESENTATIVE: 74
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 6673
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:2713924 USPATFULL Full-text
TITLE: CAS INDEXING IS AVAILABLE FOR THIS PATENT.
INVENTOR(S): Hale, Ron L., Woodside, CA, UNITED STATES
Rabinowitz, Joshua D., Princeton, NJ, UNITED STATES
Solas, Dennis W., San Francisco, CA, UNITED STATES
Zaffaroni, Alejandro C., Atherton, CA, UNITED STATES
Alexza Pharmaceuticals, Inc., Palo Alto, CA, UNITED STATES (U.S. corporation)

PATENT ASSIGNEE(S) :

PATENT INFORMATION:
APPLICATION INFO.: US 2003-735496 20030326 (11)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-792012, filed on 3 Mar 2004, GRANTED, Pat. No. US 7018621
Continuation of Ser. No. US 2002-155621, filed on 22 May 2002, GRANTED, Pat. No. US 6759029
Continuation-in-part of Ser. No. US 2004-76574, filed on 27 Jan 2004, GRANTED, Pat. No. US 7045118
Continuation of Ser. No. US 2003-735496, filed on 12 Dec 2003, GRANTED, Pat. No. US 705121 Continuation of Ser. No. US 2002-154594, filed on 23 May 2002, GRANTED, Pat. No. US 6740309 Continuation-in-part of Ser. No. US 2004-792239, filed on 3 Mar 2004, GRANTED, Pat. No. US 7014840 Continuation of Ser. No. US 2002-155705, filed on 22 May 2002, GRANTED, Pat. No. US 6805854

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L18 ANSWER 2 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2006:302361 USPATFULL Full-text
TITLE: Substituted indole compounds having NOS inhibitory activity
INVENTOR(S): Maclafford, Shawn, Mississauga, CANADA
Rannau, Jallal, Brampton, CANADA
Rakhit, Sumai, Mississauga, CANADA
Patman, Joanne, Mississauga, CANADA
Renton, Paul, Toronto, CANADA

PATENT INFORMATION:
APPLICATION INFO.: US 2001-294203P 20010524 (60)
FILE SEGMENT: US 2001-317479P 20010905 (60)
US 2001-332280P 20011121 (60)
US 2001-336118P 20011030 (60)
US 2001-294203P 20010524 (60)
US 2001-317479P 20010905 (60)

APPLICATION
MERCK AND CO., INC., P O BOX 2000, RAHWAY, NJ.
07055-0907, US

FILE SEGMENT:
DOCUMENT TYPE: Utility
LEGAL REPRESENTATIVE: SPANSON & BRATSCHUN L.L.C., SUITE 330, HIGHLANDS RANCH, CO, 80129, US
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1
LINE COUNT: 1385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 11 USPATFULL on STN
ACCESSION NUMBER: 20061:175340 USPATFULL Full-text
TITLE: Benzodiazepine cgrp receptor antagonists
INVENTOR(S): Burgey, Christopher S., Philadelphia, PA, UNITED STATES
Stump, Craig A., Pottstown, PA, UNITED STATES
Williams, Theresa M., Harleysville, NJ, UNITED STATES
NUMBER KIND DATE
PATENT INFORMATION: US 2006148790 A1 20060706
US 7196019 B2 20070327 (10)
US 2004-362298 A1 20040624
WO 2004-US20206 20051222 PCT 371 date
NUMBER DATE
PRIORITY INFORMATION: US 2003-60482674 200310626
DOCUMENT TYPE: Utility
FILE SEGMENT:
LEGAL REPRESENTATIVE: MERCK AND CO., INC., P O BOX 2000, RAHWAY, NJ,
07065-0907, US
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 2196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I: ##STR1## (where variables R, sup. 1, R, sup. 2, R, sup. 3, R, sup. 6, R, sup. 7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 11 USPATFULL on STN
ACCESSION NUMBER: 20061:159976 USPATFULL Full-text
TITLE: Benzodiazepine cgrp receptor antagonists
INVENTOR(S): Burgey, Christopher S., UNITED STATES
NUMBER DATE
PATENT INFORMATION: US 2006135511 A1 20060522
US 2004-562297 A1 20040624 (10)
WO 2004-US20209 20051222 PCT 371 date
DOCUMENT TYPE: Utility

APPLICATION
MERCK AND CO., INC., P O BOX 2000, RAHWAY, NJ.
07055-0907, US

FILE SEGMENT:
DOCUMENT TYPE: Utility
LEGAL REPRESENTATIVE: 1
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 2148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of Formula I: I (where variables R, ##CUSTOM-CHARACTER-00001## 1?, R, ##CUSTOM-CHARACTER-00002## / 2?, R, ##CUSTOM-CHARACTER-00003## 3?, R, ##CUSTOM-CHARACTER-00004## 4?, R, ##CUSTOM-CHARACTER-00005## 6?, R, ##CUSTOM-CHARACTER-00006## 7?, G, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 6 OF 11 USPATFULL on STN
ACCESSION NUMBER: 20061:125492 USPATFULL Full-text
TITLE: 3-'2-(Dimethylamino) ethyl: n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof
INVENTOR(S): Rajan, Srinivasan Thirumalai, Hyderabad, IN, UNITED STATES
Murthy, Mokkalarla Suryanarayana, Hyderabad, IN, UNITED STATES
Prasad, Achampeta Kodanda Ram, Hyderabad, IN, UNITED STATES
Dr. Reddy's Laboratories Limited, Hyderabad 500 016, Andhra Pradesh, INDIA (non-U.S. corporation)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 7 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004-261840 USPATFULL Full-text
TITLE: NR2b receptor antagonists for the treatment or prevention of migraines
INVENTOR(S): Allen, Christopher, Doylestown, PA, UNITED STATES
Roblan, Ken S., Carversville, PA, UNITED STATES

Sleeth, Timothy, Blue Bell, PA, UNITED STATES

PATENT INFORMATION:		NUMBER	KIND	DATE
US 2004/214341	A1	US 2003-47923	A1	20041014
WO 2002-1552069		WO 2002-1552069		20031205 (10)

migraine

Cohen, Marlene L., Carmel, IN, United States
Johnston, Kirk W., Indianapolis, IN, United States
Phabos, Lee A., Fountain, IN, United States
Eli Lilly and Company, Indianapolis, IN, United States
(U.S. corporation)

PATENT ASSIGNEE (S) :

PATENT INFORMATION:		NUMBER	KIND	DATE
US 2001-297672P		US 2001-0612	(60)	Utility
APPLICATION				
MERCK AND CO INC.	P O BOX 2000,	RAHWAY, NJ,	070650907	
NUMBER OF CLAIMS:	20			
EXEMPLARY CLAIM:	1			
LINE COUNT:	5753			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses a method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines. The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist or a 5HT_{1B/1D} agonist for the treatment or prevention of migraines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 8 OF 11 USPATFULL on STN
ACCESSION NUMBER: 2004-209899 USPATFULL Full-text
TITLE: Rapid absorption selective 5-HT agonist formulations
INVENTOR(S): Mezaache, Naima, McLean, VA, UNITED STATES
Mezaache, Delilia, Laurel, MD, UNITED STATES
Prisbree, Steve, Reston, VA, UNITED STATES
Maes, Paul, Toronto, CANADA

PATENT INFORMATION:		NUMBER	KIND	DATE
US 2004/162333	A1	US 2004-779784	A1	20040519 (10)
APPLICATION INFO.:				

PATENT INFORMATION:		NUMBER	KIND	DATE
US 2003-447741P		US 2003-0219	(60)	Utility
APPLICATION				
CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O.				
BOX 14300, WASHINGTON, DC, 20044-4300				
NUMBER OF CLAIMS:	135			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	17			
LINE COUNT:	2725			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides for a rapid absorption pharmaceutical composition comprising an effective amount of at least one selective 5-HT agonist, at least one spheronization aid and at least one solubility enhancer. The composition of the invention is incorporated into microparticles, which may be subsequently taste-masked and incorporated into a variety of dosage forms for administration to a patient suffering from migraine

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 9 OF 11 USPATFULL on STN
ACCESSION NUMBER: 1998-45217 USPATFULL Full-text
TITLE: Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of

PATENT INFORMATION:

DOCUMENT TYPE: FILE SEGMENT: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: LINE COUNT: CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention comprises comprising administering to a mammal methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 10 OF 11 USPATFULL on STN
ACCESSION NUMBER: 91-62807 USPATFULL Full-text
TITLE: Indole derivative
INVENTOR(S): Oxford, Alexander W., Royston, England
Glaxo Group Limited, England (non-U.S. corporation)
PATENT ASSIGNEE (S) :

PATENT INFORMATION:		NUMBER	KIND	DATE
US 5037845		US 1989-317682	(7)	Priority information: APPLICATION INFO.: Continuation of Ser. No. US 1987-82666, filed on 7 Aug 1987, now abandoned which is a continuation of Ser. No. US 1989-317682, filed on 1 Aug 1985, now abandoned
RELATED APPLN. INFO.:				

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Continuation of Ser. No. US 1987-82666, filed on 7 Aug 1987, now abandoned which is a continuation of Ser. No. US 1989-317682, filed on 1 Aug 1985, now abandoned

PATENT INFORMATION:		NUMBER	KIND	DATE
US 5037845		US 1989-317682	(7)	PRIORITY INFORMATION: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: LINE COUNT: CAS INDEXING IS AVAILABLE FOR THIS PATENT.
RELATED APPLN. INFO.:				AB A compound of formula (I) #STR1## and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L18 ANSWER 11 OF 11 USPAT2 on STN
ACCESSION NUMBER: 2006-173340 USPAT2 Full-text
TITLE: Benzodiazepine CGRP receptor antagonists

INVENTOR(S) :

Burgey, Christopher S., Philadelphia, PA, UNITED STATES

Stump, Craig A., Pottstown, PA, UNITED STATES

Williams, Theresa M., Marlboro, NJ, UNITED STATES

Merck & Co, Inc., Rahway, NJ, UNITED STATES (U.S.

corporation)

PATENT ASSIGNEE(S) :

PATENT INFORMATION:	NUMBER	KIND	DATE
US 7196079	B2		20070327
WO 200500807			20050106
US 2004-562298			20040624 (10)
WO 2004-US20206			20040624
			20051222 PCT 371 date

PRIORITY INFORMATION:	NUMBER	DATE
US 2003-482674P		20030626 (60)

DOCUMENT TYPE: UTILITY

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Kifle, Bruck

LEGAL REPRESENTATIVE: Rose, David L., Rubin, David

NUMBER OF CLAIMS: 16

EXEMPLARY CLAIM: 1

LINE COUNT: 1945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of Formula I:

##STR1## (where variables R₁-R₁₀, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

>> log hold	COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
		88.86	276.41

FULL ESTIMATED COST

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:30:56 ON 04 APR 2007

=> d ibib abs 106

L11 ANSWER 106 OF 106
ACCESSION NUMBER: 2002-12064 USPAT2 Full-text
TITLE: Rapid-melt semi-solid compositions, methods of making
same and methods of using same
INVENTOR(S): Cherukuri, Subraman Rao, Vienna, VA, United States
PATENT ASSIGNEE(S): capricorn pharma, Inc., Frederick, MD, United States
(U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.: US 6589556 B2 20030708 (9)
RELATED APPLN. INFO.: US 2001-058835 Continuation-in-part of Ser. No. US 2000-610489, filed
on 5 Jul 2000, now patented, Pat. No. US 6375982
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE: Spear, James M.
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1516
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, a gastrointestinal therapeutic or a migraine therapeutic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 105

L11 ANSWER 105 OF 106
ACCESSION NUMBER: 2002-18243 USPAT2 Full-text
TITLE: Porous paclitaxel matrices and methods of manufacture
thereof
INVENTOR(S): Straub, Julie, Winchester, MA, United States
Bernstein, Howard, Cambridge, MA, United States
Chickering, III, Donald E., Framingham, MA, United States
Khattak, Sarvat, Amherst, MA, United States
Randall, Greg, Somerville, MA, United States
AcuspHERE, Inc., Cambridge, MA, United States (U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.: US 6610317 B2 20030826 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-US14578, filed on 25 May 2000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PRIORITY INFORMATION:

US 2000-186310P 20000302 (60)

US 1999-15659P 19991008 (60)

US 1999-136333P 19990527 (60)

DOCUMENT TYPE:

Utility

GRANTED

FILE SEGMENT:

PRIMARY EXAMINER: Dees, Jose G.

ASSISTANT EXAMINER: Devitt, Robert M

LEGAL REPRESENTATIVE: Holland & Knight LLP

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT INFORMATION:

US 2004-158099 USPAT2 Full-text

APPLICATION INFO.: 2004-158099 USPAT2 Full-text

Title: Buccal, polar and non-polar spray or capsule containing

drugs for treating disorders of the central nervous

32

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)

LINE COUNT: 275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 111 and sumatriptan/clm

L12 51 L11 AND SUMATRIPTAN/CLM

=> d ibib abs 51

L12 ANSWER 51 OF 51 USPAT2 on STN
ACCESSION NUMBER: 2002-12064 USPAT2 Full-text
TITLE: Rapid-melt semi-solid compositions, methods of making
same and methods of using same
INVENTOR(S): Cherukuri, Subraman Rao, Vienna, VA, United States
(U.S. corporation)

NUMBER KIND DATE

US 6589556 B2 20030708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT INFORMATION:

US 2001-858885 Continuation-in-part of Ser. No. US 2000-610489, filed

on 5 Jul 2000, now patented, Pat. No. US 6375982

UTILITY

GRANTED

FILE SEGMENT:

PRIMARY EXAMINER:

Fubara, Blessing

ASSISTANT EXAMINER:

Nath & Associates PLLC, Nath, Gary M., Meyer, Jerald L.

LEGAL REPRESENTATIVE:

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel rapid-melt, semi-solid molded composition, including methods of making the same, and methods of using the same for the delivery of prophylactic and therapeutic active materials to a mammal wherein the prophylactic or therapeutic active is a psychotropic, a gastrointestinal therapeutic or a migraine therapeutic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 50

L12 ANSWER 50 OF 51 USPAT2 on STN

ACCESSION NUMBER: 2004-158099 USPAT2 Full-text

TITLE:

INVENTOR(S) : Dugger, III, Harry A., Flemington, NJ, UNITED STATES
PATENT ASSIGNEE(S) : NovaDel Pharma, Inc., Flemington, NJ, UNITED STATES
(U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.: US 6977070 B2 20051220 (10)
RELATED APPLN. INFO.: US 2003-726585 Division of Ser. No. US 2002-230050, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Haghisharian, Mina
LEGAL REPRESENTATIVE: Dickstein Shapiro Morin & Oshinsky LLP
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1
LINE COUNT: 986
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

>> d ibib abs 49

L13 ANSWER 49 OF 51 USPAT2 on STN 2004:158:00 USPAT2 Full-text
ACCESSION NUMBER: 2004:158:00 USPAT2 Full-text
TITLE: Buccal, polar and non-polar spray or capsule containing drugs for treating pain
INVENTOR(S) : Dugger, III, Harry A., Flemington, NJ, UNITED STATES
PATENT ASSIGNEE(S) : NovaDel Pharma, Inc., Flemington, NJ, UNITED STATES
(U.S. corporation)

PATENT INFORMATION:
APPLICATION INFO.: US 6969508 B2 20051129 (10)
RELATED APPLN. INFO.: US 2003-726525 Division of Ser. No. US 2002-230050, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Haghisharian, Mina
LEGAL REPRESENTATIVE: Dickstein Shapiro Morin & Oshinsky LLP
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1
LINE COUNT: 821
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

>> s 112 and sumatriptan/ab

L13 10 L12 AND SUMATRIPTAN/AB

>> d ibib abs tot

L13 ANSWER 1 OF 10 USPATFULL on STN 2006:274081 USPATFULL Full-text
ACCESSION NUMBER: Taste masked sumatriptan tablets and processes for their preparation
TITLE: Mathur, Rajeev Shankar, Delhi, INDIA
INVENTOR(S) : Kumar, T. Vijaya, Andhra Pradesh, INDIA
Roy, Sunilendu Bhushan, Maharashtra, INDIA
Malik, Rajiv, Wein, Austria
NUMBER KIND DATE
US 2006233875 A1 20061019
US 2003-521402 A1 20030717 (10)
WO 2003-1B2838 PCT 371 date
20060301
NUMBER DATE
IN 2002-7592002 20020719

PRIORITY INFORMATION:
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: RANBAXY INC., 600 COLLEGE ROAD EAST, SUITE 2100,
PRINCETON, NJ, 08540, US
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 749
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 10 USPATFULL on STN 2006:196517 USPATFULL Full-text
ACCESSION NUMBER: Amorphous (sumatriptan) succinate
TITLE: Rajan, Srinivasan Thirumalai, Hyderabad, INDIA
INVENTOR(S) : Murthy, Mokkarsala Suryanarayana, Hyderabad, INDIA
Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA
NUMBER KIND DATE
US 2006167274 A1 20060727
US 2006-386608 A1 20060322 (11)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-62399, filed on 25 Jul 2003, GRANTED, Pat. No. US 7034162

INVENTOR(S) : RUDOLF, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF DOODS, Henri, Warthausen, GERMANY, FEDERAL REPUBLIC OF MUELLER, Stephan Georg, Warthausen, GERMANY, FEDERAL REPUBLIC OF REPUBLIC OF DR. REDDY'S LABORATORIES, INC., 200 SOMERSET CORPORATE BLVD., SEVENTH FLOOR., BRIDGEWATER, NJ, 08807-2862, US	
DOCUMENT TYPE: Utility	
FILE SEGMENT: LEGAL REPRESENTATIVE:	
NUMBER OF CLAIMS: 17	
EXEMPLARY CLAIM: 1	
NUMBER OF DRAWINGS: 1	
DRAWING PAGE(S): 1 Drawing Page(s)	
LINE COUNT: 264	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB The present invention relates to an amorphous form of Sumatriptan succinate of Formula (1). The present invention also relates to a process for the preparation of an amorphous form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrile solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L13 ANSWER 3 OF 10 USPATFULL on STN	
ACCESSION NUMBER: 2006194849 USPATFULL Full-text	
TITLE: Buccal, polar and non-polar spray containing Sumatriptan	
INVENTOR(S) : Dugger, Harry A. III, Flemington, NJ, UNITED STATES	
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES	
NUMBER DATE	
PATENT INFORMATION: US 2006165604 A1 20060727	
APPLICATION INFO.: US 2006-166663 A1 20060303 (11)	
RELATED APPLN. INFO.: Division-Of Ser. No. US 2003-671710, filed on 29 Sep 2003, PENDING Continuation-in-part of Ser. No. US 2002-230059, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-537118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING	
DOCUMENT TYPE: Utility	
FILE SEGMENT: APPLICATION DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP, 2101 L Street, NW, Washington, DC, 20037, US	
LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: 42	
EXEMPLARY CLAIM: 1-11	
NUMBER OF DRAWINGS: 1 Drawing Page(s)	
LINE COUNT: 944	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II: aqueous polar solvent sumatriptan, optionally flavoring agent and propellant; formulation III: non-polar solvent, sumatriptan, optional flavoring agent, and propellant; formulation IV: non-polar solvent, sumatriptan, optional flavoring agent, and optional flavoring agent; formulation V: a mixture of a polar solvent and a non-polar solvent, sumatriptan, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, sumatriptan, optional flavoring agent, and propellant.	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L13 ANSWER 4 OF 10 USPATFULL on STN	
ACCESSION NUMBER: 2006167762 USPATFULL Full-text	
TITLE: Use of selected CGRP-antagonists in combination with	
NUMBER DATE	
PATENT INFORMATION: US 2006106227 A1 20060518	
APPLICATION INFO.: US 2004-516597 A1 20040616 (10)	
WO 2004-US15004 20040616 (10)	
PCT 371 date 20050705	

NUMBER	DATE
PRIORITY INFORMATION : IN 2002-45102 Utility	20030613
DOCUMENT TYPE : FILE SEGMENT	20030613
LEGAL REPRESENTATIVE : DR.-REDDY'S LABORATORIES, INC., 200 SOMERSET CORPORATE BLVD, SEVENTH FLOOR., BRIDGEWATER, NJ, 08807-2862, US	
NUMBER OF CLAIMS : 1	47
EXEMPLARY CLAIM : 1	8 Drawing Page(s)
NUMBER OF DRAWINGS : LINE COUNT : 672	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB	A process for the preparation of highly pure Sumatriptan id described. A process for the preparation of novel crystalline Form I and crystalline Form II of Sumatriptan succinate is described. Sumatriptan is used for alleviating the pain of migraine headaches.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L13 ANSWER 6 OF 10 USPATFULL ON STN ACCESION NUMBER : TITLE : Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same	US 20060105 USPATFULL Full-text
INVENTOR(S) : Ahmed, Salah U., New City, NY, UNITED STATES Li, Lianli, Pomona, NY, UNITED STATES Naini, Venkatesh, Parsippany, NJ, UNITED STATES	US 2006005989 A1 20060105 (11)
NUMBER	KIND DATE
PATENT INFORMATION : APPLICATION INFO. : US 2005-149444 A1 20050610 (11)	US 2005-578286P 20040610 (60)
NUMBER	DATE
PRIORITY INFORMATION : DOCUMENT TYPE : FILE SEGMENT	US 2004-578286P 20040610 (60)
LEGAL REPRESENTATIVE : STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005, US	US 2004143002 A1 20040722
NUMBER OF CLAIMS : EXEMPLARY CLAIM : 1	US 7034162 B2 20060425
NUMBER OF DRAWINGS : LINE COUNT : 973	US 2003-627399 A1 20030725 (10)
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
AB	The present invention is directed to pharmaceutical compositions comprising sumatriptan succinate and sodium caprate for increased absorption of sumatriptan succinate across biological membranes. The invention is also directed to methods of making the pharmaceutical compositions and uses thereof.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L13 ANSWER 7 OF 10 USPATFULL ON STN ACCESION NUMBER : TITLE : INVENTOR(S) :	US 2005-38196 USPATFULL Full-text Pharmaceutical compositions comprising sumatriptan and meclopropramide, and methods of use thereof Vergnault, Guy, Loecle, FRANCE
NUMBER	KIND DATE
PATENT INFORMATION : APPLICATION INFO. : US 2005032876 A1 20050210	US 2004-888324 A1 20040709 (10)
NUMBER	DATE

PRIORITY INFORMATION : GB 2003-17904 DOCUMENT TYPE : Utility	20030731
FILE SEGMENT ; LEGAL REPRESENTATIVE : Daniel F. Coughlin, Esq., Mintz Levin Cohn Ferris Glorsky and Pope PC, Chrysler Center, 666 Third Avenue, New York, NY, 10017	
NUMBER OF CLAIMS : 20	CLM-001-9
EXEMPLARY CLAIM : 618	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LINE COUNT : 1	AB The invention is concerned with a unit dosage form containing sumatriptan and metoclopramide. The unit dosage form is so configured that a portion of the sumatriptan dose is present in a first phase adapted for immediate release of sumatriptan, and a second portion is contained in a second phase adapted for the sustained release of sumatriptan.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L13 ANSWER 8 OF 10 USPATFULL ON STN ACCESION NUMBER : TITLE : Amorphous form of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methane sulfonamide succinate (sumatriptan succinate).	2004-185116 USPATFULL Full-text
INVENTOR(S) : Reddy, Manne Satyanarayana, Hyderabad, INDIA Rajan, Srinivasan Thirumalai, Hyderabad, INDIA Murthy, Mokkalla Suravanyara, Hyderabad, INDIA Prasad, Achampeta Kodanda Ram, Hyderabad, INDIA	US 2004143002 A1 20040722
PATENT ASSIGNEE (S) : DR. REDDY'S LABORATORIES LIMITED (non-U.S. corporation) DR. REDDY'S LABORATORIES, INC. (non-U.S. corporation)	US 7034162 B2 20060425
NUMBER	KIND DATE
PATENT INFORMATION : APPLICATION INFO. : US 2004143002 A1 20040722	US 2003-627399 A1 20030725 (10)
NUMBER	DATE
PRIORITY INFORMATION : DOCUMENT TYPE : FILE SEGMENT	US 2002-5942002 20020812
LEGAL REPRESENTATIVE : LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023	
NUMBER OF CLAIMS : 1	1 Drawing Page(s)
EXEMPLARY CLAIM : 1	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
NUMBER OF DRAWINGS : LINE COUNT : 282	AB The present invention relates to an amorphous form of Sumatriptan succinate of an amorphous form of Sumatriptan succinate. The process for the preparation of an amorphous Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrolic solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L13 ANSWER 9 OF 10 USPATFULL ON STN ACCESION NUMBER : TITLE : sumatriptan Dugger, Harry A., III, Flemington, NJ, UNITED STATES Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES	2004-177749 USPATFULL Full-text
INVENTOR(S) :	Buccal, polar and non-polar spray containing

form of Sumatriptan succinate. The process for the preparation of an amorphous form of Sumatriptan succinate comprises refluxing an aqueous mixture of Sumatriptan or its succinate salt in alcoholic solvents such as methanol or nitrite solvents such as acetonitrile followed by evaporation of the solvent from the filtrate. The resulting residue is triturated with water immiscible aromatic or aliphatic hydrocarbon solvents such as cyclohexane to afford an amorphous form of Sumatriptan succinate.

DOCUMENT TYPE: PENDING
FILE SEGMENT: APPLICATION
PATENT INFORMATION: US 2004-135913 A1
APPLICATION INFO.: US 2003-671710 A1
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-230059, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-337118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

NUMBER	KIND	DATE
US 2004-135913	A1	20040715
US 2003-671710	A1	20030929 (10)
Continuation-in-part of Ser. No. US 2002-230059, filed on 29 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2000-337118, filed on 29 Mar 2000, PENDING Continuation-in-part of Ser. No. WO 1997-US17899, filed on 1 Oct 1997, PENDING		

UTILITY

APPLICATION

JONES DAY, 222 EAST 41ST ST., NEW YORK, NY, 10017

68

NUMBER OF CLAIMS:

1

NUMBER OF DRAWINGS:

1

EXEMPLARY CLAIM:

1 Drawing Page(s)

LINE COUNT: 1167

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II: aqueous polar solvent, sumatriptan, optionally flavoring agent, and propellant; formulation III: non-polar solvent, sumatriptan, and optional flavoring agent; formulation IV: non-polar solvent, sumatriptan, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, sumatriptan, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, sumatriptan, optional flavoring agent, and propellant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 10 USPAT2 ON STN
ACCESSION NUMBER: 2004-185116 USPAT2 Full-text
TITLE: Amorphous form of 3-[2-(dimethylamino)ethyl-N-methyl-1H-indole-5-methane sulfonamide succinate (sumatriptan succinate)

INVENTOR(S): Reddy, Manne Satyanarayana, Hyderabad, INDIA

Rajan, Srinivasan Thirumalai, Hyderabad, INDIA

Murthy, Mokkala Surendra, Hyderabad, INDIA

Prasad, Achampeta Kondala Ram, Hyderabad, INDIA

Dr. Reddy's Laboratories Limited, Hyderabad, INDIA

(non-U.S. corporation)

Dr. Reddy's Laboratories, Inc., Upper Saddle River, NJ,

UNITED STATES (U.S. corporation)

NUMBER	KIND	DATE
US 7034162	B2	20060425
US 2003-627399		20030725 (10)

NUMBER

KIND

DATE

IN 2000-5942002 20000812

UTILITY GRANTED

SOLOLA, Taofiq

Shiao, Robert

Franks, Robert A., Cepeda, Milagros A., Pergament,

Edward D.

16

1 Drawing Figure(s); 1 Drawing Page(s)

266

LINE COUNT: CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an amorphous form of Sumatriptan succinate of Formula

(1). The present invention also relates to process for the preparation of an amorphous